Business

Citrine Global Subsidiary Files in the U.S. Patent & Trademark Office a Provisional Patent Application for “PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE USE OF CANNABIS & RELATED PRODUCTS&rdqu

Citrine Global Subsidiary Files in the U.S. Patent & Trademark Office a Provisional Patent Application for “PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE USE OF CANNABIS & RELATED PRODUCTS&rdqu.

articleCitrine Global Corp.November 2, 20213/company/citrine-global-corp/news/citrine-global-subsidiary-files-in-the-us-patent-and-trademark-office-a-provisional-patent-application-for-pharmaceutical-compositions-and-methods-for-the-treatment-of-side-effects-associated-with-the-use-of-cannabis-and-related-productsandrdqu
Citrine Global Subsidiary Files in the U.S. Patent & Trademark Office a Provisional Patent Application for “PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE USE OF CANNABIS & RELATED PRODUCTS&rdqu

About this update from Citrine Global Corp.

[{"type":"text","content":"\n Tel Aviv, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Citrine Global, Corp. (OTCQB: CTGL) is pleased to announce that its subsidiary, Cannovation Center Israel Ltd., has filed in the U.S. Patent & Trademark Office a provisional patent application for \"PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE USE OF CANNABIS, CANNABINOIDS, AND RELATED PRODUCTS\". The invention addresses technologies and solutions to support medical cannabis patients who experience side effects related to their cannabis treatment. Research shows that many medical cannabis patients experience side effects such as headaches, dry mouth and dry eyes, lightheadedness and dizziness, drowsiness, fatigue, nausea, vomiting, disorientation, hallucinations, increased heart rate, increased appetite, impaired judgement, impaired coordination, and more. Some medical cannabis patients continue treatment despite experiencing side effects, while research shows that at least 15% choose to discontinue treatment despite good clinical outcomes achieved with the cannabis treatment (1. We found that there is an unmet market need of addressing side effects of cannabis treatment. This need is further emphasized by the projected growth of the medical cannabis market forecasted to nearly triple from $16 billion in 2021 to $46 billion in 2026 )2. The filing of the patent application advances our ongoing botanical and cannabis-related research and planned clinical trials on wellness to pharma solutions and products. We developed and commercialized the Green Botanicals product line of nutritional supplements to be offered as complementary products to be sold SIDE BY SIDE with cannabis products & solutions. Our strategy is to market the Green Botanicals nutritional supplements in collaboration with cannabis distribution channels, pharmacies, dispensers, and leading cannabis companies worldwide with all products meeting the relevant regulatory approvals in every territory of sale. Ms. Ora Elharar Soffer, Citrine Global’s Chairperson and Chief Executive Officer stated: “We filed the provisional patent application for “PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE USE OF CANNABIS, CANNABINOIDS, AND RELATED PRODUCTS” and following our research of cannabis-related-side-effec...

More updates from Citrine Global Corp.